UNSPSC 51311702: Phenyltoloxamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K65LB6598J, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine but generally known as phenyltoloxamine, which bears US NIH Compound Identifier 7077. European Medicines Agency schedules Phenyltoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09791MIG.

UNSPSC 51311702 Phenyltoloxamine is a Commodity code that, based on recent state and local solicitations, captures pharmaceutical products and related drug-management systems procured by public health and human services agencies. The code's nominal scope does not align cleanly with the recent opportunities posted under it; the most recent and substantive solicitations concern naloxone and drug deactivation systems, generic multi-source pharmaceuticals distributed through cooperative purchasing, and exploratory procurement around direct-to-manufacturer prescription programs. State and local governments buying under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving state and local facilities, school districts, and participating jurisdictions across multiple states.

Activity under the code spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, responding by July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities around direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, seeking generic pharmaceuticals and OTC products from manufacturers for distribution through authorized wholesalers to participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026 and contract effectiveness July 1, 2026.